{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "Apixaban",
    "comparative_drug": "Dalteparin",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "",
    "target_disease": "",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "10 mg BID for first 7 days, then 5 mg BID",
    "dalteparin_dosing": "200 IU/kg daily for first month, then 150 IU/kg daily",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "pre-filled syringes",
    "scheduled_visits": [
        "Screening (up to specified days before Day 1)",
        "Visit 1 (Day 1)",
        "Visit 2",
        "Visit 3",
        "Visit 4",
        "Visit 5",
        "Visit 6",
        "Visit 7",
        "Visit 8",
        "Early Discontinuation (E/D)",
        "Follow-up (Month 7 from randomization)"
    ],
    "primary_efficacy_outcome": "",
    "secondary_efficacy_outcomes": [],
    "primary_safety_outcome": "",
    "secondary_safety_outcomes": [],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": []
}